Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Huy Phan

Clinical Cardiac Electrophysiology Chandler, AZ Medical Doctor

NPI 1447368840 CMS profile 19798

595 N. Dobson Road, Suite A5, Chandler, AZ 85224

Open in the dashboard

General payments

$27,894

569 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$73,486 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Huy Phan of Chandler, AZ is reported in the CMS Open Payments database as having received $27,894 across 569 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $73,486 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 60th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,603 79
2024 General $4,209 75
2023 General $5,120 78
2022 General $1,274 55
2021 General $3,892 105
2020 General $3,899 86
2019 General $3,897 91

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Huy Phan
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Huy Phan were reported at $5,603. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Huy Phan Clinical Cardiac Electrophysiology median Middle half National median
2019 $3,897 $2,361 $585–$8,260 $163
2020 $3,899 $993 $247–$4,351 $114
2021 $3,892 $1,185 $326–$4,739 $132
2022 $1,274 $2,073 $554–$6,789 $149
2023 $5,120 $2,568 $759–$8,159 $160
2024 $4,209 $2,557 $703–$7,403 $164
2025 $5,603 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $4,714 58 payments
  2. Boston Scientific Corporation $3,835 109 payments
  3. Abbott Laboratories $2,818 51 payments
  4. CardioFocus, Inc. $2,626 10 payments
  5. Medtronic, Inc. $2,223 15 payments
  6. Biosense Webster, Inc. $2,147 31 payments
  7. Medical Device Business Services, Inc. $2,072 16 payments
  8. Atricure, Inc. $1,912 26 payments
  9. Sanofi-Aventis U.S. LLC $568 30 payments
  10. Janssen Pharmaceuticals, Inc $480 29 payments
  11. Other $4,500 194 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,756 524 payments
  2. Travel and Lodging $9,205 35 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,750 4 payments
  4. Education $167 5 payments
  5. Consulting Fee $16 1 payment
Products named General payments · program years 2019–2025
  1. LifeVest $4,714 58 payments
  2. Carto 3 $2,235 20 payments
  3. Heartlight System $1,312 5 payments
  4. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $1,194 11 payments
  5. Carto 3 System $1,132 14 payments
  6. AMPLATZER AMULET $849 5 payments
  7. ATRICLIP LAA EXCLUSION SYSTEM $834 11 payments
  8. AVEIR $488 6 payments
  9. XARELTO $480 29 payments
  10. Rapiblyk $471 1 payment
  11. Other $10,667 397 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

3,202

Median for Cardiology: 2,533

Drug cost

$937,573

Median for Cardiology: $485,213

Branded share of claims

34.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 353 $419,204
Multaq Dronedarone Hcl Brand 198 $246,278
Xarelto Rivaroxaban Brand 133 $140,786
Entresto Sacubitril/Valsartan Brand 48 $55,471
Flecainide Acetate Generic 260 $10,206
Droxidopa Generic 24 $9,687
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 25 $8,259
Midodrine Hcl Generic 98 $5,382
Enoxaparin Sodium Generic 134 $4,538
Amiodarone Hcl Generic 155 $4,364

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$470,652

Medicare's payments for the services billed

Medicare patients

756

Average age 77

Services billed

4,210

374 women, 382 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 68%
Arthritis 49%
Ischemic heart disease 42%
Chronic kidney disease 32%
Diabetes 31%
Heart failure 26%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $100
  • PFIZER INC. $41
$140 353 —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $93
$93 198 —
Ozempic
  • Novo Nordisk Inc $48
$48 — —
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $40
$40 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $36
$36 133 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

569 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record